Volume 31, Number 1 (1-2017)                   Med J Islam Repub Iran 2017 | Back to browse issues page




DOI: 10.18869/mjiri.31.4
PMID: 28638811
PMCID: PMC5473015

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mobaraki H, Azami-Aghdash S, Sarabi Asiabar A, Rezapour A, Kafaei Mehr M H, Emamgolizadeh S. Cost-effectiveness of eplerenone in treatment of cardio-vasculardiseases: a systematic review. Med J Islam Repub Iran. 2017; 31 (1) :13-22
URL: http://mjiri.iums.ac.ir/article-1-4037-en.html

Health Management and Economics Research Center, Iran University of Medical Sci-ences, Tehran, Iran. , m.h_kafa@yahoo.com
Abstract:   (1120 Views)

Introduction: In recent years, a few studies have been conducted in the area of the cost-effectiveness of the Eplerenone; it's notable that coherent and clear evidence are not available. Therefore, this study aimed to systematically review studies of cost-effectiveness of Eplerenone in the treatment of cardio-vascular patients.

Methods: This systematic review study was conducted in 2016. The required information were collected by using key Mesh words from databases such as: Google scholar, PubMed, Science Direct, MagIran, SID, Scopus and hand searching journals and selected articles references. The Quality of selected articles was assessed by the Drummond's check-list.

Results: Nine articles were included from 296 articles found in literature review. Studies have been conducted in 8 countries (America, Britain, Australia, Switzerland, France, Spain, the Netherlands and Canada). In general, the cost-effectiveness of Eplerenone was investigated on 31757 in treating cardio-vascular patients. Average of quality-adjusted life years (QALY) in studies with non-modeling was equal to 0.0908 in terms of Framingham approach, 0.0595 in terms of Saskatchewan approach and 0.1309 in terms of Worcester approach. In general, the overall average cost of treating cardiovascular patients with Eplerenone was equal to $6694 of America in one year. The cost per additional (QALY) was estimated to be $ 9478 of America. Incremental cost-effectiveness ratio was high in the United States compared to European countries. The Average quality of articles was estimated about 7.4 from 10.

Conclusion: Based on the results of the studies reviewed in this study, it seems that Eplerenone has acceptable cost-effectiveness compared with current treatments, placebo and similar drugs.

Full-Text [PDF 997 kb]   (454 Downloads)    

Send email to the article author